Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET · CHIMERIC PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P07949. Start with cancer, then reuse UniProt P07949 as the stable protein anchor across project notes and exports.
Start with cancer, then reuse UniProt P07949 as the stable protein anchor across project notes and exports.
Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.
Start review with cancer because it currently carries approved-linked support. Linked drugs include PRALSETINIB, SELPERCATINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyProto-oncogene tyrosine-protein kinase receptor Ret
Review this target as Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET, mapped to UniProt P07949. ChEMBL maps the protein component as Proto-oncogene tyrosine-protein kinase receptor Ret. Sequence length is 1114 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET as ChEMBL target CHEMBL3430888, mapped to UniProt P07949. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET is the right protein anchor across sources, using UniProt P07949 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why cancer is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET |
| Target Type | CHIMERIC PROTEIN |
| Organism | Homo sapiens |
| UniProt | P07949 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Proto-oncogene tyrosine-protein kinase receptor Ret |
| UniProt Accession | P07949 |
| Component Type | Protein |
| Sequence Length | 1114 aa |
Proto-oncogene tyrosine-protein kinase receptor Ret
Review this target as Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET, mapped to UniProt P07949. ChEMBL maps the protein component as Proto-oncogene tyrosine-protein kinase receptor Ret. Sequence length is 1114 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block.
Start review with cancer because it currently carries approved-linked support. Linked drugs include PRALSETINIB, SELPERCATINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL5618101 | 8.92 | IC50 | 1.2 | Preclinical |
| CHEMBL388978 | 8.82 | IC50 | 1.51 | Preclinical |
| CHEMBL4644274 | 8.77 | IC50 | 1.7 | Preclinical |
| CHEMBL4643578 | 8.48 | IC50 | 3.3 | Preclinical |
| CHEMBL5171764 | 8.3 | IC50 | 5.0 | Preclinical |
| CHEMBL4636056 | 8.27 | IC50 | 5.4 | Preclinical |
| CHEMBL4634073 | 8.22 | IC50 | 6.0 | Preclinical |
| CHEMBL4639022 | 8.2 | IC50 | 6.3 | Preclinical |
| CHEMBL169390 | 8.15 | IC50 | 7.0 | Preclinical |
| CHEMBL4790634 | 8.05 | IC50 | 8.86 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 16 | 76 | 6.4 |
| protein format | 3 | 6 | 8.0 |